How much funding has A2 Biotherapeutics raised?

A2 Biotherapeutics has raised $208.5M in total funding, most recently a Series C round.

Who are A2 Biotherapeutics's investors?

A2 Biotherapeutics's investors include Nextech Invest, Vida Ventures, Section 32, The Column Group, Samsara BioCapital, Sherpa Healthcare Partners.

When was A2 Biotherapeutics founded?

A2 Biotherapeutics was founded in 2018.

Where is A2 Biotherapeutics headquartered?

A2 Biotherapeutics is headquartered in Agoura Hills, California, United States.

What industry is A2 Biotherapeutics in?

A2 Biotherapeutics operates in Biotech, Healthcare, Oncology.

A2 Biotherapeutics

Innovating New Treatments for Solid Tumors

Agoura Hills, United States · Founded 2018 · $208.5M raised

Biotech

Healthcare

Oncology

Headquarters: Agoura Hills, California
Founded: 2018
Business Model: B2B
Website: a2bio.com

Total Funding: $208.5M
Last Round: $80.0M Series CJan 2025
Rounds: 3

About

A2 Biotherapeutics is a clinical-stage cell therapy company developing first-in-class logic-gated CAR T-cell therapies for solid tumors using its proprietary Tmod technology platform. Founded in 2018 by Alexander Kamb, Michael Gallo, and Paul Kang, the company is headquartered in Agoura Hills, California, and is advancing multiple T-cell programs targeting cancers with unmet need.

Summary

A2 Biotherapeutics is a Biotech company based in Agoura Hills, United States, founded in 2018. It has raised $208.5M in total across 3 rounds, most recently a $80.0M Series C round in Jan 2025. Investors include Nextech Invest, Vida Ventures and Section 32.